-+ 0.00%
-+ 0.00%
-+ 0.00%

Abbisko Cayman Reports Positive Phase II Results for Oral PD-L1 Inhibitor ABSK043 in NSCLC Combination Therapy

路透·12/08/2025 00:00:45

登錄查看新聞詳情